Flamant M - Search Results

1

Golimumab for the treatment of ulcerative colitis.

Flamant M, Paul S, Roblin X. Flamant M, et al. Expert Opin Biol Ther. 2017 Jul;17(7):879-886. doi: 10.1080/14712598.2017.1327576. Epub 2017 May 16. Expert Opin Biol Ther. 2017. PMID: 28472597 Free PMC article. Review.

2

[Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets].

Flamant M, Bourreille A. Flamant M, et al. Rev Med Interne. 2007 Dec;28(12):852-61. doi: 10.1016/j.revmed.2007.06.008. Epub 2007 Jun 26. Rev Med Interne. 2007. PMID: 17628232 Review. French.

3

Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.

Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip JM, Bigard MA, Peyrin-Biroulet L. Oussalah A, et al. Among authors: flamant m. Aliment Pharmacol Ther. 2009 Oct 15;30(8):854-63. doi: 10.1111/j.1365-2036.2009.04097.x. Aliment Pharmacol Ther. 2009. PMID: 19764940 Free article.

4

Could therapeutic drug monitoring of anti-TNF-α be useful to consider a de-escalation of treatment?

Flamant M, Roblin X. Flamant M, et al. Expert Opin Biol Ther. 2015;15(11):1657-60. doi: 10.1517/14712598.2015.1069273. Epub 2015 Jul 20. Expert Opin Biol Ther. 2015. PMID: 26190418

5

Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.

Flamant M, Rigaill J, Paul S, Roblin X. Flamant M, et al. Drugs. 2017 Jul;77(10):1057-1068. doi: 10.1007/s40265-017-0755-8. Drugs. 2017. PMID: 28523588 Review.

6

Inflammatory bowel disease: towards a personalized medicine.

Flamant M, Roblin X. Flamant M, et al. Therap Adv Gastroenterol. 2018 Jan 10;11:1756283X17745029. doi: 10.1177/1756283X17745029. eCollection 2018. Therap Adv Gastroenterol. 2018. PMID: 29383027 Free PMC article. Review.

7

Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.

Roblin X, Riviere P, Flamant M, Veyrard P, Poullenot F, Paul S, Laharie D. Roblin X, et al. Among authors: flamant m. Inflamm Bowel Dis. 2018 Aug 16;24(9):1904-1909. doi: 10.1093/ibd/izy069. Inflamm Bowel Dis. 2018. PMID: 29726958 Review.

8

DIAMOND study: an additional evidence of the interest of being proactive in IBD.

Roblin X, Flamant M. Roblin X, et al. Among authors: flamant m. Ann Transl Med. 2018 Jul;6(13):279. doi: 10.21037/atm.2018.06.30. Ann Transl Med. 2018. PMID: 30094265 Free PMC article. No abstract available.

9

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease.

Bouguen G, Huguet A, Amiot A, Viennot S, Cholet F, Nachury M, Flamant M, Reimund JM, Desfourneaux V, Boureille A, Siproudhis L; GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives). Bouguen G, et al. Among authors: flamant m. Clin Gastroenterol Hepatol. 2020 Mar;18(3):628-636. doi: 10.1016/j.cgh.2019.05.027. Epub 2019 May 22. Clin Gastroenterol Hepatol. 2020. PMID: 31128337 Free article.

10

Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.

Ferrante M, Schirbel A, Pierik MJ, Haas T, Flamant M, Khalifa A, Philip G, Cornillie F, Meehan AG, Govoni M. Ferrante M, et al. Among authors: flamant m. Eur J Gastroenterol Hepatol. 2022 Jun 1;34(6):646-654. doi: 10.1097/MEG.0000000000002374. Epub 2022 Apr 8. Eur J Gastroenterol Hepatol. 2022. PMID: 35412484

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page